Archives: Contractor Email

This update contains important information for community pharmacy teams, including details of the ongoing response to the COVID-19 pandemic.

BSO ALERTS

CPNI ALERTS 

HSCB ALERTS 

Please bring this to the attention of your pharmacy team(s).
Pharmacy team(s) can keep updated via CPNI’s

Or report medicine shortages or pricing issues via the CPNI’s Medicine Shortage Reporter.

Kind regards

SENT ON BEHALF OF 
DR. GARETH C. GILVARY
Governance & Support Pharmacist

Dear Colleague

The following concessionary prices have been granted for July 2021:

DrugPack SizeConcessionary Price
Baclofen 10mg tablets84£3.30
Loratadine 5mg/5ml oral solution100ml£7.75
Mebeverine 135mg tablets100£4.40
Pregabalin 100mg capsules84£5.42
Tolbutamide 500mg tablets28£16.79
Trimethoprim 50mg/5ml oral suspension sugar free100ml£11.94
Ursodeoxycholic acid 250mg capsules60£11.98

This is the second update of concessionary prices for July 2021.

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Concessionary prices may be granted up until the end of the month so CPNI will notify you of any further concessionary prices as and when they are agreed.

Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
DR. GARETH C. GILVARY
Governance & Support Pharmacist

Dear Colleague
The following concessionary prices have been granted for July 2021:
DrugPack SizeConcessionary Price
Eplerenone 25mg tablets28£11.95
Eplerenone 50mg tablets28£15.53
Etoricoxib 60mg tablets28£6.00
Etoricoxib 90mg tablets28£8.35
Naftidrofuryl 100mg capsules84£7.84
Olmesartan medoxomil 20mg tablets28£6.44
Olmesartan medoxomil 40mg tablets28£10.35
Pregabalin 75mg capsules56£4.18
Sodium fluoride 0.05% mouthwash sugar free250ml£1.74
Sulfasalazine 500mg gastro-resistant tablets112£17.52
Sulfasalazine 500mg tablets112£16.50

This is the first update of concessionary prices for July 2021.

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Concessionary prices may be granted up until the end of the month so CPNI will notify you of any further concessionary prices as and when they are agreed.

Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
DR. GARETH C. GILVARY
Governance & Support Pharmacist

This update contains important information for community pharmacy teams, including details of the ongoing response to the COVID-19 pandemic.

BSO ALERTS 

  • Weekly Drug Alerts are available here.MPS 2793 – Medicines Notification – Tetralysal 300mg hard capsules 6 July 2021
  • Weekly Shortages Information is available here.
  • Serious Shortage Protocols are available here.

CPNI ALERTS 

HSCB ALERTS 

Please bring this to the attention of your pharmacy team(s).

Pharmacy team(s) can keep updated via CPNI’s

Or report medicine shortages or pricing issues via the CPNI’s

Kind regards

SENT ON BEHALF OF 
DR. GARETH C. GILVARY
Governance & Support Pharmacist

Dear Colleague
Please find correspondence HERE for the attention of all Community Pharmacies offering Living Well service, from HSCB Pharmacy & Medicines Management.

SUMMARY

  • The last campaign of 2020/2021, How are you feeling?, finished on 31 May 2021.
  • Pharmacies offering Living Well are required to complete an online evaluation survey for this campaign.
  • It is vital that all pharmacies contracted to provide “Living Well” submit their evaluation survey as it allows HSCB to collate data to demonstrate the value and impact of the service to other sectors. Additionally, it supports future commissioning and service development. 
  • The HSCB monitors compliance with the service requirements, in particular evaluation submission. Should your pharmacy fail to submit an evaluation survey response, the HSCB reserves the right to recover all, or part of, this funding via an adjustment to the pharmacy’s BSO payment account.

ACTION

  • Contractors are asked to review the correspondence.
  • Pharmacies offering Living Well service are required to complete an evaluation survey, available HERE by 19 July 2021.
  • If you have already completed this, you do not need to do anything further. 

Kind regards

SENT ON BEHALF OF
DR. GARETH C. GILVARY
Governance & Support Pharmacist

Dear Colleagues,

Further to HSCB COVID-CPVS Update 25 issued on Friday 2 July 2021. I write to advise that Contractors and Pharmacy Staff providing commissioned COVID-19 vaccination services may find the option to administer a second dose of AZ vaccine to patients presenting at the pharmacy, who have received their first AZ vaccine from another provider, helpful in minimising the occurrence of vaccine waste in the pharmacy as a result of either vaccine overage in the AZ vials or in instances of cancelled or missed appointments (DNA’s) in community pharmacy vaccination schedules.

HSCB COVID-CPVS Update 25 contains specific information and conditions that need to be complied with should your pharmacy be asked by a patient to administer a second dose AZ vaccine where the patient received the first dose AZ vaccine from another provider. 

HSCB will be writing to General Practitioners asking that they continue to provide second dose AZ vaccines to any of their patients for whom they have administered the first dose AZ vaccine, so community pharmacies should see such requests in the pharmacy as the exception rather than the norm. 

Contractors should not feel obligated to facilitate such requests and may refer the patient back to the initial, or other, provider.

CPNI will also be meeting with HSCB to review the COVID-CPVS remuneration model in light of additional resource, time, staff and expense incurred by contractors since the roll-out of the COVID vaccination programme in the community pharmacy setting.

Please do not hesitate to contact CPNI offices should you require any additional information or clarity.

Kinds regards

SENT ON BEHALF OF GERARD GREENE
Chief Executive